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Abstract
Background: Chronic diseases such as chagasic megaesophagus (secondary to Chagas’ disease) have been
suggested as etiological factors for esophageal squamous cell carcinoma; however, the molecular mechanisms
involved are poorly understood.
Objective: We analyzed hotspot PIK3CA gene mutations in a series of esophageal squamous cell carcinomas
associated or not with chagasic megaesophagus, as well as, in chagasic megaesophagus biopsies. We also checked
for correlations between the presence of PIK3CA mutations with patients’ clinical and pathological features.
Methods: The study included three different groups of patients: i) 23 patients with chagasic megaesophagus associated
with esophageal squamous cell carcinoma (CM/ESCC); ii) 38 patients with esophageal squamous cell carcinoma not
associated with chagasic megaesophagus (ESCC); and iii) 28 patients with chagasic megaesophagus without esophageal
squamous cell carcinoma (CM). PIK3CA hotspot mutations in exons 9 and 20 were evaluated by PCR followed by direct
sequencing technique.
Results: PIK3CA mutations were identified in 21.7% (5 out of 23) of CM/ESCC cases, in 10.5% (4 out of 38) of ESCC and
in only 3.6% (1 case out of 28) of CM cases. In the CM/ESCC group, PIK3CA mutations were significantly associated with
lower survival (mean 5months), when compared to wild-type patients (mean 2.0 years). No other significant
associations were observed between PIK3CA mutations and patients’ clinical features or TP53 mutation profile.
Conclusion: This is the first report on the presence of PIK3CA mutations in esophageal cancer associated with chagasic
megaesophagus. The detection of PIK3CA mutations in benign chagasic megaesophagus lesions suggests their
putative role in esophageal squamous cell carcinoma development and opens new opportunities for targeted-
therapies for these diseases.
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Introduction
Esophageal cancer is the eighth most frequent type of
cancer in the world and the sixth most lethal, occurring
mainly in developing countries such as Brazil [1]. The
most frequent histological subtype is esophageal squa-
mous cell carcinoma (ESCC), accounting for 90% of
cases, especially in high-risk areas [2]. The main risk fac-
tors for ESCC are alcohol consumption, tobacco (mainly
in association) and hot-beverage consumption [3]. It is
also reported that chronic diseases, such as the chagasic
megaesophagus, can be associated with ESCC develop-
ment [4].
Chagasic megaesophagus is the late manifestation of
Chagas’ disease (caused by the protozoan Trypanosoma
cruzi) [5]. Direct infection of Trypanosoma cruzi will
lead to destruction of the intramural myenteric neurons
in the esophagus, causing inflammation and production
of neurotoxins. This will result in uncoordinated con-
tractions and reduction of peristalsis of the organ, alter-
ing the functioning of the lower esophageal sphincter
and progressive dilation of the esophagus (megaesopha-
gus) [6]. In Brazil, one of the endemic regions of Chagas’
disease, approximately 4 million people are infected with
the parasite and about 6–7% of these patients will de-
velop chagasic megaesophagus [5]. Patients affected with
this lesion are more likely to develop ESCC (3–10%)
when compared to the general population [4].
The carcinogenic mechanisms of ESCC development
in the context of chagasic megaesophagus have been lit-
tle explored. Recently, our group showed the high fre-
quency (13/32, 40.6%) of TP53 mutations in ESCC
associated with chagasic megaesophagus [7]. Moreover,
we also reported the presence of microsatellite instability
(MSI) in a small fraction (1/19, 5.3%) of cases [8]. How-
ever, many other genes are known to be involved in
ESCC carcinogenesis as demonstrated by the TCGA
consortium [9].
One of these genes is the PI3KCA, which encodes the
protein phosphatidylinositol 3-kinase (PI3K), that
belongs to a family of lipid kinases that encodes the
p110α catalytic subunit [10]. PI3K is a quite complex
signaling pathway since it regulates cell growth, prolifer-
ation, cell motility, the production of new proteins,
apoptosis and cell survival [10]. Therefore, its activation
will lead to many downstream pathways that regulate
several cellular functions, including those involved in the
development of cancer [10, 11]. Recurrent PI3KCA
oncogenic mutations were identified in several types of
tumors, including colorectal, breast, ovary, gastric, and
recently in ESSC [12]. The mutations occur mainly in
exons 9 (E542K and E545K) and 20 (H1047R) [12].
Recently, it was shown that PIK3CA mutations, namely
H1047R, also disrupt cellular genetic stability, increasing
the frequency of chromosomal errors and leading to
tetraploidy [13]. Importantly, therapeutic strategies tar-
geting the PIK3/Akt signaling pathway have been devel-
oped and could constitute effective treatment options
for patients harboring PI3KCA mutations [14].
Therefore, in the current study we performed the muta-
tion analysis of PIK3CA gene in patients with ESCC and
chagasic megaesophagus associated or not with ESCC,
and searched for associations between the mutation status
and patients’ clinical and pathological features.
Materials and methods
Study population
In this retrospective study, we analyzed 89 formalin-fixed
paraffin-embedded (FFPE) tissues of three groups of
patients: i) 23 patients with chagasic megaesophagus asso-
ciated with esophageal squamous cell carcinoma (CM/
ESCC); ii) 38 patients with esophageal squamous cell car-
cinoma without chagasic megaesophagus (ESCC); and iii)
28 patients with chagasic megaesophagus without esopha-
geal squamous cell carcinoma (CM). All chagasic megae-
sophagus patients were serologic positive for Chagas’
disease and/or had exams (imaging and histopathology)
that confirmed the presence of megaesophagus. The
patients with esophageal squamous cell carcinoma
without chagasic megaesophagus were all serologic
negative for Chagas’ disease and had exams (imaging and
histopathology) that confirmed malignant disease. These
patients were previously described for their
clinical-pathological and molecular TP53 and MSI fea-
tures [7, 8].
The samples were obtained from patients treated be-
tween 1990 and 2016 in three different institutions from
the Southeast of Brazil, namely: Barretos Cancer Hos-
pital, Barretos, São Paulo State; Federal University of
Triângulo Mineiro (UFTM), Uberaba, Minas Gerais
State and São Paulo State University (UNESP), Botucatu,
São Paulo State. All clinical and pathological information
was obtained through medical record review.
DNA isolation
Following tissue macro-dissection, DNA was isolated
from FFPE tissue representative of the tumor lesions in
ESCC and CM/ESCC groups and esophageal tissues in
CM group, as previously described [7]. Briefly, the tumor
area was delineated in a hematoxylin-eosin stained (HE,
Merck KGaA, GE) section by a pathologist, and the
marked area was scraped by scalp from 3 to 5 10 μm un-
stained slides into a 1,5 ml tube. Afterwards, the tissue
was subjected to the dewaxing step by heating (80 °C –
20min), followed by sequential washing in xylol (5 min)
and decreasing concentrations of ethanol (1 min - 100,
70 and 50%) and nuclease-free water9 (1 min). DNA iso-
lation was performed using the QIAamp DNA Micro
Kit (Qiagen) following the manufacture’s protocol.
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PIK3CA mutation analysis
Polymerase chain reaction (PCR) followed by direct se-
quencing (Sanger method) was performed for the analysis
of hotspot mutations (exons 9 and 20) of the PIK3CA
gene as previously described [15]. The PCR was per-
formed on the 89 samples under the following conditions:
5X Flexi Buffer (pH 8.5) and 25mM MgCl2 (Promega,
USA), 200 μM dNTPmix (Invitrogen, USA), 200 nM
primers exon 9 (forward 5’-CTGTGAATCCAGAGGGGA
AA-3′ and reverse 5’-ACATGCTGAGATCAGCCAA
AT-3′) and exon 20 (forward 5’-ATGATGCTTGGCTC
TGGAAT-3′ and reverse 5’-GGTCTTTGCCTGCT
GAGAGT-3′), 1.25 U GoTaq®Hot Start Polymerase (Pro-
mega, USA), and nuclease-free water (Gibco, BRL, Life
Technologies, USA) in a final volume of 25 μl and 5 μl of
DNA at 50 ng/μl from each patient were added [15].
Amplification was performed in a thermocycler according
to the protocol: 96 °C for 15min, followed by 40 cycles at
96 °C for 45 s, 55.5 °C for 45 s and 72 °C for 45 s and final
extension of 72 °C for 10min, followed by a hold at 4 °C.
PCR products were subjected to 1.5% agarose gel electro-
phoresis with Gel Red (Biotium, Hayward, CA) to evaluate
the amplification of the gene of interest.
After agarose gel validation, we purified the prepar-
ation using the enzyme ExoSap-IT (GE Technology,
Cleveland, USA), followed by the sequencing reaction
using BigDye Terminator v3.1 (Applied Biosystems,
USA) and 3.2 μM of specific primers and re-purified
with xTerminator (Life Technology). The products were
sequenced using the 3500 series Genetic Analyzer Capil-
lary Sequencer (Applied Biosystems, USA). All the cases
that showed mutations were confirmed with a new PCR
reaction and direct sequencing.
Statistical analysis
Characterization of the study population was performed
through frequency tables for qualitative variables, and
measures of central tendency and dispersion (mean,
standard deviation, minimum and maximum) for the
quantitative variables, comparing the different groups.
To verify the association between PIK3CA mutation
status and clinical groups, pathological and molecular
features, Chi-square or Fisher’s exact tests were applied.
We performed an overallsurvival analysis using the
Kaplan-Meier limit estimator and the Log-rank test to
compare the survival curves between the groups.
Table 1 The clinical-pathological features of the three groups of patients
Variable Groups (n = 89)
Category CM/ESCC (n = 23) ESCC (n = 38) CM (n = 28) p-value
Gender Female 4 (17.4%) 7 (18.4%) 4 (14.3%) 0.937**
Male 19 (82.6%) 31 (81.6%) 24 (85.7%)
Age (years) Mean (SD) 59 (11) 57 (9) 59 (11) 0.039***
Min - Max 37–76 36–75 37–76
Alcohol consumption No 7 (31.8%) 8 (21.1%) 20 (71.4%) < 0.001*
Yes 15 (68.2%) 30 (78.9%) 8 (28.6%)
Missing 11 0 0
Tobacco consumption No 4 (18.2%) 6 (15.8%) 16 (57.1%) < 0.001*
Yes 18 (81.8%) 32 (84.2%) 12 (42.9%)
Missing 1 0 0
Tumor differentiation Well differentiated 5 (22.7%) 7 (19.4%) NA 0.639**
Moderate differentiated 16 (72.7%) 24 (66.7%) NA
Poorly differentiated 1 (4.5%) 5 (13.9%) NA
Missing 1 2 NA
TNM Staging I/II 4 (23.5%) 16 (42.1%) NA 0.235*
III/IV 13 (76.5%) 22 (57.9%) NA
Missing 6 0 NA
Megaesophagus grades GI/GII 10 (45.5%) NA 4 (14.3%) 0.025*
GIII/GIV 12 (54.5%) NA 24 (85.7%)
Missing 1 NA 0
*Chi-square association test; **Fisher’s exact test; ***Analysis of variance. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell
carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; CM – chagasic megaesophagus without esophageal squamous cell
carcinoma; SD - standard deviation; NA – not applicable; Bold numbers - statistical significance
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The level of significance adopted was 5% (p ≤ 0.05).
Statistical analyzes were in SPSS software v.21.0.
Results
Characterization of the population
The clinical-pathological characteristics of the patients
in the three groups are described in Table 1. The
mean age of the patients was higher in the chagasic
groups (Table 1). As already reported in our previous
studies [7], concerning risk factors for esophageal
cancer, the ESCC and CM/ESCC groups were statisti-
cally associated with higher tobacco and alcohol con-
sumption (Table 1).
Mutation analysis of PIK3CA gene
The PIK3CA mutation analysis showed the presence of
mutations in 21.7% of patients in CM/ESCC group,
followed by 10.5% in ESCC group and 3.6% in CM group
(Fig. 1 and Table 2). The frequency of mutations was simi-
lar in exons 9 and 20 (Table 3). With the exception of three
variants (A1027D, K1030R and T1053K), all the other
mutations have already been reported in the Catalogue of
Somatic Mutations in Cancer database – COSMIC (http://
cancer.sanger.ac.uk/cosmic) (Fig. 2 and Table 3).
No significant associations were observed between the
PIK3CA mutation status and patients pathological fea-
tures (Table 4). Furthermore, we assessed the role of
PIK3CA mutations on patients’ overall survival in both
groups affected by cancer (CM/ESCC and ESCC) (Fig. 3).
In CM/ESCC group, we observed that the presence of
PIK3CA mutations was significantly associated with a
lower survival rate from the diagnosis of cancer com-
pared to wild-type patients (Fig. 3a). The mean patients’
overall survival in cases from the CM/ESCC group
mutated for the PIK3CA was 5 months, in comparison
with 2.0 years for wild-type PIK3CA patients (Log-rank,
p < 0.001) (Table 5).
Additionally, we evaluated the association of PIK3CA
and TP53 mutation status, and no association was found
(Table 4).
Fig. 1 Electropherogram of PIK3CA gene. Exon 9 – wild-type sequence and mutated sequence (D549H). Exon 20 – wild-type sequence and
mutated sequence (H1047R)
Table 2 Frequency of PIK3CA mutations in the three study groups
Variable Groups (n = 89)
Category CM/ESCC (n = 23) ESCC (n = 38) CM (n = 28) p-value
PIK3CA gene WT 18 (78.3%) 34 (89.5%) 27 (96.4%) 0.132**
MUT 5 (21.7%) 4 (10.5%) 1 (3.6%)
**Fisher’s exact test. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma
without chagasic megaesophagus; CM – chagasic megaesophagus without esophageal squamous cell carcinoma. WT – wild-type; MUT – mutant; N – number
of cases
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Discussion
Among the several risk factors for the development of
ESCC, the chagasic megaesophagus (late complication of
Chagas’ disease) has been a minor etiological factor and
little explored [4]. Nevertheless, Chagas’ disease is still
an important public health problem, particularly in
Latin-America, where approximately 20 million people
are infected with Chagas’ disease and approximately 6–
7% of these people will develop chagasic megaesophagus
[5, 16].
In the present study, we investigated the frequency of
PIK3CA mutations in regions of hotspot (exons 9 and
20) in patients with chagasic megaesophagus associated
with esophageal squamous cell carcinoma (CM/ESCC)
and compared with patients with esophageal squamous
cell carcinoma without chagasic megaesophagus (ESCC)
and patients with chagasic megaesophagus without
esophageal squamous cell carcinoma (CM). We ob-
served that patients in the CM/ESCC group had a higher
frequency of mutations (5/23, 21.7%) followed by pa-
tients in the ESCC group (4/38, 10.5%), and in the CM
group (1/28, 3.6%). This is the first report of PIK3CA
mutation in ESCC that developed in the context of cha-
gasic megaesophagus and the significant frequency of
mutations (~ 22%) suggest that PIK3CA plays an import-
ant role in the carcinogenesis of CM/ESCC patients.
Moreover, the presence of PIK3CA mutation in a benign
lesion further supports the putative role of chagasic
megaesophagus as an ESCC-related condition. The fre-
quency of mutations identified in our study is in line with
that reported in the literature for ESCC patients, with fre-
quencies varying from 2.2 to 32.8% (Table 6) [9, 17–33].
This variation can be due to several factors, such as type
of tissue (frozen vs FFPE), distinct methodologies for
mutation screening and distinct ethnic groups of patients.
(Table 6).
The PIK3CA gene is often mutated in several tumors
types and most of its mutations occur in hotspot
regions, such as E542K and E545A located in the helical
domain (exon 9), and H1047R and H1047L in the kinase
domain (exon 20) [11]. These mutations lead to the acti-
vation of the PIK3 pathway and have a great potential in
oncogenic activities [11]. Interestingly, most of these
mutations (E545A, H1047R and H1047L) occurred in
Table 3 Profile of oncogenic PIK3CA mutations in the three study groups
Group Sample ID Exon Codon Codon (WT – MUT) Type of mutation Amino acids change Nature of mutation COSMIC ID
CM/ESCC 111 T 9 545 GAG – GCA A→ C E545A Missense COSM12458
122 T 9 549 GAT – CAT G→ C D549H Missense COSM219119
114 T 20 1027 GCC – GAC C→ A A1027D Missense Not reported
119 T 20 1047 CAT – CTT A→ T H1047L Missense COSM776
124 T 20 1047 CAT–CGT A→ G H1047R Missense COSM775
ESCC 26 T 9 545 GAG – GCG A→ C E545A Missense COSM12458
120 T 9 555 AGG – AAG G→ A R555K Missense COSM1716158
36 T 9 524 AGG – AAG G→ A R524K Missense COSM53245
4 T 20 1030 AAA – AGA A→ G K1030R Missense Not reported
CME 101 M 20 1053 ACA – AAA C→ A T1053K Missense Not reported
CME/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic
megaesophagus; CME – chagasic megaesophagus without esophageal squamous cell carcinoma. A – adenine; C – cytosine; G – guanine; T – thymine. WT – wild-
type; MUT – mutant
Fig. 2 PIK3CA protein and missense mutation overview
Munari et al. Infectious Agents and Cancer           (2018) 13:43 Page 5 of 9
patients in the CM/ESCC group and only one (E545A)
in one patient in the ESCC group. We also identified other
previously described important mutations (Table 3), the
D549H mutation observed in the CM/ESCC group was
reported in vulva and hepatocellular cancer [34]; R524K
mutation found in the ESCC group was reported in colo-
rectal cancer [35]; and the R555K mutation was reported
in ovary cancer [36]. Interestingly, it is important to note
that we identified three mutations in exon 20 that have
not yet been reported (A1027D and K1030R in CM/ESCC
group; T1053K in CM group). All these mutations
occurred in patients with chagasic megaesophagus whose
mutational profile of PIK3CA was never reported.
Importantly, we observed that CM/ESCC patients har-
boring PIK3CA mutations were associated with lower
overall survival, suggesting its role as a prognostic bio-
marker in this group of patients. Interestingly, the
results of our analyzes of the survival of the mutated
Table 4 Association between PIK3CA mutation status with main clinical-pathological features in the three groups
Variable PIK3CA gene
CM/ESCC group ESCC group CM group
Category WT MUT p-value WT MUT p-value WT MUT p-value
Alcohol consumption No 6 (35.3%) 1 (20%) 1.000** 7 (21.2%) 1 (20%) 1.000** 19 (70.4%) 1 (100%) 1.000**
Yes 11 (64.7%) 4 (80%) 26 (78.8%) 4 (80%) 8 (29.6%) 0 (0%)
Tobacco consumption No 4 (23.5%) 0 (0%) 0.535** 5 (15.2%) 1 (20%) 1.000** 15 (100%) 1 (100%) 1.000**
Yes 13 (76.5%) 5 (100%) 28 (84.8%) 4 (80%) 12 (44.4%) 0 (0%)
Tumor differentiation Well 4 (22.2%) 1 (25%) 1.000** 7 (22.6%) 0 (0%) 0.171** NA NA NA
Moderate 13 (72.2%) 3 (75%) 21 (67.7%) 3 (60%) NA NA
Poorly 1 (5.6%) 0 (0%) 3 (9.7%) 2 (40%) NA NA
TNM Staging I e II 4 (28.6%) 0 (0%) 0.541** 15 (46.9%) 1 (20%) 0.421** NA NA NA
III e IV 10 (71.4%) 3 (100%) 17 (53.1%) 4 (80%) NA NA
Megaesophagus degree GI/GII 7 (41.2%) 3 (60%) 0.406** NA NA NA 3 (11.1%) 1 (100%) 0.143**
GIII/GIV 10 (58.8%) 2 (40%) NA NA 24 (88.9%) 0 (0%)
TP53 gene [7] WT 9 (50%) 2 (40%) 1.000** 20 (60.6%) 2 (40%) 0.632** 26 (96.3%) 1 (100%) 1.000**
MUT 9 (50%) 3 (60%) 13 (39.4%) 3 (60%) 1 (3.7%) 0 (0%)
**Fisher’s exact test; ***Analysis of variance. CME/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal
squamous cell carcinoma without chagasic megaesophagus; CME – chagasic megaesophagus without esophageal squamous cell carcinoma. N – number of cases;
SD – standard deviation; NA – not applicable; WT – wild-type; MUT – mutated
Fig. 3 Cumulative survival of patients associated with the PIK3CA gene status. The red curves represent patients with mutation and the blue
curves represent wild-type patients. a CM/ESCC – chagasic megaesophagus associated with squamous cell carcinoma of the esophagus; b ESCC –
squamous cell carcinoma of the esophagus; MUT – mutant; WT – wild-type
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patients differ from those reported by others studies,
especially in regions of some risk such as Asia, in which
patients with ESCC with mutations of the PIK3CA gene
had a favorable overall survival compared to patients
wild-type [37].
Notably, inhibitors of the PIK3-Akt-mTOR pathway
have been developed as cancer target therapy alterna-
tives, and patients harboring PIK3CA gene mutations
could be potential candidates for such therapeutic
approach [14]. Interestingly, phase I and II clinical trials
using pan-PIK3CA agents (PIK3-class I), such as bupar-
lisib (BKM120), an oral agent that affects α, β, γ and δ
isoforms of PI3K [38], showed efficacy in several solid
tumors, including head and neck cancer [39]. Copanlisib
(BAY80–6946), an intravenous agent that affects α and δ
isoforms of PI3K, also showed promising results in
non-Hodgkin’s lymphomas [40]; as well as pictilisib
(GDC-0941), an oral agent that affects γ and δ isoforms
of PI3K, where a good response was reported in breast,
colorectal, ovarian and non-small cell lung cancer [41].
Therefore, we can hypothesize that a subset of ESCC
and CM/ESCC patients with PIK3CA mutations may
benefit from these targeted-therapies and consequently
improve their dismal survival.
In conclusion, this is the first study that analyzed and
identified PIK3CA activating mutations in patients with
esophageal squamous cell carcinomas associated with
chagasic megaesophagus (CM/ESCC), which were asso-
ciated with a worse outcome. Moreover, the identifica-
tion of mutations in benign chagasic megaesophagus
suggests their putative role in the etiology of esophageal
squamous cell carcinoma and opens new opportunities
for the treatment of these neglected patients with
targeted-therapies.
Table 5 The time and average of patients’ overall survival according to PIK3CA mutation status
Groups Time
Variable Total N events 6 months 1 year 3 years 5 years Median survival p-value
CM/ESCC WT 13 10 79.4% 72.2% 43.3% 28.9% 2 years < 0.001*
MUT 5 5 20.0% 0.0% 0.0% 0.0% 5months
ESCC WT 24 22 82.6% 64.7% 32.6% 14.5% 2 years 0.405
MUT 4 4 80.0% 80.0% 60.0% 0.0% 2.5 years
*Log-rank test. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without
chagasic megaesophagus; WT – wild-type; MUT – mutated; Bold numbers - statistical significance
Table 6 Frequency of PIK3CA mutations identified in patients with esophageal squamous cell carcinoma worldwide
References Year Country (Region) Patients of study PIK3CA mutated (%) Type of sample Techniques
Mori et al. [24] 2008 Japan 88 2.2% FT Direct Sequencing
Wang et al. [30] 2013 China 76 3.9% FT Direct Sequencing
Akagi et al. [17] 2009 Japan 52 7.7% FFPE Direct Sequencing
Kim et al. [21] 2016 Korea 534 10.5% FFPE Direct Sequencing
Phillips et al. [25] 2006 Australia 35 11.8% FFPE Direct Sequencing
Zheng et al. [33] 2016 China 79 19.7% FT Pyrosequencing
Shigaki et al. [27] 2013 China 219 21.0% FT Pyrosequencing
Liu et al. [23] 2017 China 210 22.9% FFPE Pyrosequencing
Baba et al. [18] 2015 Japan 440 23.0% FFPE Pyrosequencing
Yang et al. [31] 2017 China 24 4.2% FFPE NGS
Song et al. [28] 2014 China 158 4.5% FT NGS
Lin et al. [22] 2014 China 139 7.0% FFPE NGS
Gao et al. [19] 2014 Japan 133 9.0% FT NGS
Sawada et al. [26] 2016 Japan 144 10.4% FT NGS
TCGA et al. [9] 2017 Western and Eastern 90 13.0% FT NGS
Yokota et al. [37] 2018 Japan 126 13.5% FFPE NGS
Zhang et al. [32] 2015 China 90 17.0% FT NGS
Wang et al. [29] 2015 USA 71 24.0% FFPE NGS
NGS – next generation sequencing; FFPE – formalin-fixed paraffin-embedded tissue; FT – fresh frozen tissue
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